CN109789178A - 影响心血管效率的营养补充剂 - Google Patents
影响心血管效率的营养补充剂 Download PDFInfo
- Publication number
- CN109789178A CN109789178A CN201780059452.9A CN201780059452A CN109789178A CN 109789178 A CN109789178 A CN 109789178A CN 201780059452 A CN201780059452 A CN 201780059452A CN 109789178 A CN109789178 A CN 109789178A
- Authority
- CN
- China
- Prior art keywords
- nutritional supplement
- astaxanthin
- haematococcus pluvialis
- extract
- nutritional
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000015872 dietary supplement Nutrition 0.000 title claims abstract description 70
- 230000002526 effect on cardiovascular system Effects 0.000 title claims abstract description 13
- 235000013793 astaxanthin Nutrition 0.000 claims abstract description 57
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims abstract description 56
- 239000001168 astaxanthin Substances 0.000 claims abstract description 56
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims abstract description 56
- 229940022405 astaxanthin Drugs 0.000 claims abstract description 56
- 241000168517 Haematococcus lacustris Species 0.000 claims abstract description 39
- 239000000284 extract Substances 0.000 claims abstract description 28
- 239000002199 base oil Substances 0.000 claims abstract description 7
- 230000036541 health Effects 0.000 claims description 17
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims description 10
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 10
- 239000002775 capsule Substances 0.000 claims description 9
- 244000163122 Curcuma domestica Species 0.000 claims description 7
- 235000003392 Curcuma domestica Nutrition 0.000 claims description 7
- 235000003373 curcuma longa Nutrition 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 7
- 235000020688 green tea extract Nutrition 0.000 claims description 7
- 235000013976 turmeric Nutrition 0.000 claims description 7
- 229940094952 green tea extract Drugs 0.000 claims description 6
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 5
- 241000717739 Boswellia sacra Species 0.000 claims description 5
- 239000004863 Frankincense Substances 0.000 claims description 5
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims description 5
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims description 5
- 239000004148 curcumin Substances 0.000 claims description 5
- 235000012754 curcumin Nutrition 0.000 claims description 5
- 229940109262 curcumin Drugs 0.000 claims description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 5
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims description 5
- 229920002674 hyaluronan Polymers 0.000 claims description 5
- 229960003160 hyaluronic acid Drugs 0.000 claims description 5
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 235000005875 quercetin Nutrition 0.000 claims description 5
- 229960001285 quercetin Drugs 0.000 claims description 5
- 229960000984 tocofersolan Drugs 0.000 claims description 5
- 239000002076 α-tocopherol Substances 0.000 claims description 5
- 235000004835 α-tocopherol Nutrition 0.000 claims description 5
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 5
- 230000000747 cardiac effect Effects 0.000 claims description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 4
- 235000018062 Boswellia Nutrition 0.000 claims description 3
- 244000269722 Thea sinensis Species 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 235000009569 green tea Nutrition 0.000 claims description 3
- 230000006872 improvement Effects 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 2
- 241001608538 Boswellia Species 0.000 claims 2
- 230000001737 promoting effect Effects 0.000 claims 2
- 239000008157 edible vegetable oil Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 3
- 239000003963 antioxidant agent Substances 0.000 abstract description 2
- 230000003078 antioxidant effect Effects 0.000 abstract description 2
- 235000006708 antioxidants Nutrition 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 239000007901 soft capsule Substances 0.000 description 14
- 239000013589 supplement Substances 0.000 description 13
- 238000012360 testing method Methods 0.000 description 10
- 235000016709 nutrition Nutrition 0.000 description 6
- 230000035764 nutrition Effects 0.000 description 5
- 238000010009 beating Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 240000007551 Boswellia serrata Species 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 241000168525 Haematococcus Species 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001514 astaxanthins Chemical class 0.000 description 1
- 230000000386 athletic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000011871 bio-impedance analysis Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/05—Chlorophycota or chlorophyta (green algae), e.g. Chlorella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/326—Foods, ingredients or supplements having a functional effect on health having effect on cardiovascular health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/18—Lipids
- A23V2250/194—Triglycerides
- A23V2250/1944—Medium-chain triglycerides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/202—Algae extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2104—Anthocyanins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/211—Carotene, carotenoids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2112—Curcumin, turmeric
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2116—Flavonoids, isoflavones
- A23V2250/21168—Quercetin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/214—Tea
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/70—Vitamins
- A23V2250/712—Vitamin E
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
公开了用于改善心血管效率的营养补充组合物。营养补充剂组合物可以包括与载体油和抗氧化剂混合的来源于雨生红球藻提取物的虾青素。还公开了相关制备方法。
Description
技术领域
本申请涉及营养治疗和补充剂领域,具体而言,涉及用于改善心血管效率的营养治疗剂和补充剂等。
背景技术
营养补充剂通常用来改善健康和/或物理机能。虽然营养补充剂可以通过适应性调整以提供特定的健康和/或机能益处,但是相对只有很少的补充剂能够提供此类改善心血管***效率的益处。
发明内容
本申请涉及营养治疗和补充剂,更具体地,涉及改善个体的心血管效率的营养治疗剂和/或补充剂。以下对不同实施例的详细描述并非旨在限制本申请的范围,而是仅仅代表不同的实施方式。
用量、浓度和其他数值数据在本文中可以以范围格式呈现。应当理解为,这样的范围格式仅用于方便和简洁表达,并且应当被灵活地解释为不仅包括明确列举为范围的限制的数值,而且还包括涵盖在该范围内的所有单独的数值或子范围,就如同每个数值和子范围被明确列举一样。例如,1mg~200mg的量应当被解释为不仅包括1mg~约200mg的明确列举的限度,而且还包括单独的量,如2mg、3mg、4mg,以及子范围,如10mg~50mg、20mg~100mg等。除非另外说明,所有范围都包括两个端点。术语“心血管效率”和“强心效应”是如在实施例1中以及在详细说明中的其他地方所描述时进行定义。
本申请公开的营养补充剂可以包括来源于雨生红球藻(Haematococcuspluvialis,H.pluvialis)的虾青素。
例如,在一些实施例中,营养补充剂包含的虾青素来源于雨生红球藻,雨生红球藻是一种来源于绿藻门红球藻科的淡水物种。这种物种因其高含量的强抗氧化剂虾青素而为人们所熟知。在其休眠细胞中存在大量的虾青素,源于环境条件变得不利于细胞正常生长时,虾青素会在细胞中产生并迅速积累。此类不利条件包括强光、高盐度和营养物质的低利用率。雨生红球藻(H.pluvialis)的亮红色是由虾青素产生的,当其暴露于直射阳光下时,虾青素被认为可以保护休眠细胞免受紫外线辐射(UV-辐射)的有害影响。
在一些实施例中,雨生红球藻(H.pluvialis)的提取物(描述Astazine spec)被用作提供虾青素的营养补充剂。在一个实施例中,营养补充剂包括:雨生红球藻提取物、可食用载体油、以及天然抗氧化剂。
在一些实施例中,可食用载体油是中链甘油三酯。
在一些实施例中,该天然抗氧化剂是D-α-生育酚。
在一些实施例中,雨生红球藻的提取物(描述Astazine spec)用作营养补充剂,提供1mg~200mg、40mg~200mg、70mg~200mg、100mg~200mg、150mg~200mg、15mg~150mg、15mg~100mg、15mg~50mg或40mg~130mg的虾青素;或提供40mg~75mg来源于雨生红球藻材料的虾青素。
除了来源于雨生红球藻材料的虾青素之外,本申请公开的一些营养补充剂可以包括以下成分中的一种或多种:绿茶、绿茶提取物、槲皮素、矢车菊素-3-葡萄糖苷(C3G)、姜黄素/姜黄、乳香(boswellia)或透明质酸。
例如,在一些实施例中,营养补充剂(例如,包装供单次使用的营养补充剂)包括量为5mg~400mg、50mg~400mg、75mg~400mg、125mg~400mg、25mg~200mg、25mg~100mg、25mg~75mg、或75mg~125mg的C3G。
在一些实施例中,营养补充剂(例如,包装供单次使用的营养补充剂)可以包括5mg~150mg的绿茶提取物。在一些实施例中,营养补充剂中绿茶提取物的用量可以在15mg~50mg之间。
在一些实施例中,营养补充剂中的透明质酸的用量可以在5mg~150mg之间。在一些实施例中,营养补充剂中姜黄素/姜黄的用量可以在15mg~250mg之间。在一些实施例中,槲皮素的用量可以在1mg~200mg之间。在一些实施例中,营养补充剂中的乳香的用量可以在约1mg~100mg之间。
在一些实施例中,营养补充剂可以配制成液体胶囊或软凝胶胶囊。例如,在一些实施例中,营养补充剂的成分可以混合到基础液体或油中用于包封。在一些实施例中,该液体或软凝胶胶囊按重量计可以在1mg~1,000mg之间。在一些实施例中,该营养补充剂可以包装用于一次性使用。
在一些实施例中,营养补充剂可以展现改善心血管性能。换言之,在一些实施例中,当给予健康成人服用时,营养补充剂对于改善心血管效率是有效的。例如,在一些实施例中,营养补充剂的补充可以引起次最大锻炼或机体活动期间的心率降低分别超过1%、2%、3%、4%、5%、6%、7%、8%、9%、或10%。
在一些实施例中,当给予健康成人此营养补充剂时,该营养补充剂对于降低需氧阈值(AeT)和厌氧阈值(AT)收缩时的心率是有效的。例如,在一些实施例中,营养补充剂可以降低健康成人的平均心率为每分钟5-20次搏动和/或每分钟10-15次搏动之间。因此,营养补充剂可以提供与心血管效率的改善相关联的一方面或多方面的健康益处。
在一些实施例中,提供了使用上述营养补充剂中的任一种来制备促进强心效应或改善心血管效率的药物。
具体实施方式
实施例1
实验设计
本研究用以评估使用包括来源于雨生红球藻的虾青素的营养补充剂胶囊的效果。更具体地,健康受试者补充12mg的虾青素8周。更具体地,虾青素营养补充剂是混合组合,其包括表1中所列成分,其也列出了同一表中的每种成分的用量。
表1
成分 | 量 |
雨生红球藻提取物 | 50% |
可食用的MCT油(中链甘油三酯) | 48% |
D-α-生育酚 | 2% |
作为背景,在运动员中,虾青素补充4周已经显示出能够在相对较高的运动强度下改善其运动机能的各种指标。例如,虾青素补充后在1200m高强度跑步之后减少了乳酸积累,并且显著改善了力量输出,并使其更快地完成了高强度的20km的自行车计时试验。
我们的实验评估了健康受试者在较高强度和较低强度运动期间补充8周的虾青素(12mg/天)对心脏呼吸功能的影响。
采取双盲平行实验设计,28位健康受试者(男性=14,女性=14,平均年龄=42)每天服用12mg虾青素AX(Haematococcus pluvialis algal extract,雨生红球藻提取物)或者安慰剂持续8周。在补充期之前和之后,对受试者进行最大跑步测试(以跑步机上的VO2max值计)和最大自行车测试(以自行车测力计上的功率值计)。
结果
在高强度锻炼条件中,服用虾青素没有改善跑步时的最大耗氧量(跑步时的VO2max值)或者最大力量输出(骑自行车时的瓦特值)。有趣的是,服用虾青素的受试者与安慰剂组相比,在次最大跑步强度下(在需氧阈值AeT和厌氧阈值AT下)显示出更低的平均心率,明显地低约10%,表明了虾青素补充组在次最大需氧耐受强度下,具有较深厚的强心效果,但是在最大强度下不显现此效果。
简言之,持续8周每天补充12mg的虾青素可使受试者心率在次最大耐受强度下降低,使其平均心率约为137bpm(需氧阈值AeT)至约146bpm(厌氧阈值AT),而不是在较高的“峰值”强度,例如,在自行车定时试验期间的152bpm或者在跑步最大VO2max的峰值的166bpm。这些效果是意料不到的,并且是一项新的发现,由此,虾青素补充剂可被认为是长距离和超远距离耐力运动员(例如,马拉松赛跑运动员、铁人三项运动员和超跑运动员/骑自行车者)的有益助剂,而对于较短距离内较高强度竞争的运动员却不是必要的。此外,这些数据还出乎意料地显示了另一项发现,由数据可知补充虾青素可产生普遍的“强心效应”,这可能有益于包括老年人在内的非运动人群,以及那些具有心脏并发症的人,心脏并发症包括心肌梗塞后期、心力衰竭、使用他汀类药物、线粒体功能障碍、慢性疲劳以及相关病症。
贯穿本说明书对“一种实施例”或“所述实施例”的引用意味着结合该实施例描述的一种特定特征、结构或特性被包括在至少一个实施例中。因此,贯穿本说明书引用的短语或其变型不一定都指代相同的实施例。
实施例2
配方2:软胶囊由含天然虾青素的雨生红球藻提取物(含有1%虾青素)制备(表2)。
表2
实施例3
配方3:软胶囊由含天然虾青素的雨生红球藻提取物(含有20%虾青素)制备(表3)。
表3
实施例4
配方4:软胶囊由含天然虾青素的雨生红球藻提取物(含有10%虾青素)制备(表4)。
表4
实施例5
配方5:软胶囊由含天然虾青素的雨生红球藻提取物(含有20%虾青素)制备(表5)。
表5
实施例6
配方6:软胶囊由含天然虾青素的雨生红球藻提取物(含有10%虾青素)制备(表6)。
表6
实施例7
配方7:软胶囊由含天然虾青素的雨生红球藻提取物(含有20%虾青素)制备(表7)。
表7
安排54个健康受试者(男性=30,女性=24,平均年龄=39)服用配方2至7的软胶囊(含有雨生红球藻提取物)补充8周,每组有9位健康受试者。在补充期之前和之后,受试者进行最大跑步测试(以在跑步机上的VO2max值计)和最大自行车测试(以在自行车测力计上的瓦特值计)。通过生物电阻抗分析来测量机体成分,包括体重、体脂百分比和基础代谢率。
跑步VO2max值评估目的是为参与者在15分钟内达到最大耗氧量和自愿性疲劳而设计的。该方案包括一个自选的逐渐热身的简单慢跑,随后每分钟逐渐增加速度和倾斜角度,直到筋疲力尽。在最大值和两个次最大水平(需氧阈值AeT和厌氧阈值AT)下记录心率(每分钟心跳,bpm)和耗氧量(ml/kg/min)。自行车功率值(瓦特)评估是以20分钟时间试验来实施的,其中参与者按指导利用自选的工作负荷和90rpm(范围在80-100rpm之间)的目标踏板节奏去产生他们的最高平均功率(瓦特值)。
结果显示,当给予所有健康受试者时,7种配方的营养补充剂对于需氧阈值(AeT)和厌氧阈值(AT)收缩时的降低心率是有效的。在次最大运动强度下,配方2至7组的平均心率为134-149bpm(需氧阈值AeT时)至131-159bpm(厌氧阈值AT时),但不在较高“峰值”强度下(例如,在自行车时间试验期间的约154-158bpm或在跑步VO2max的峰值处的约165-172bpm)。在所有配方组中,次最大跑步心率从需氧阈值(AeT)的1%-10%和厌氧阈值(AT)的1%-9.8%下降,其中配方2组(虾青素和绿茶提取物)和配方4(虾青素和C3G)组的心率显著低于补充之前。给予补充之前和之后相比,在实施例2组中,受试者的需氧阈值(AeT)时平均心率降低了8.9%,受试者的厌氧阈值(AT)时平均心率降低了8.0%,并且实施例4组是实施例1至7组中的最佳组。在实施例4组中,需氧阈值(AeT)时平均心率降低了12.2%,厌氧阈值(AT)时平均心率降低了9.8%。
实施例8
配方8:软胶囊由含天然虾青素的雨生红球藻提取物(含有10%虾青素)制备(表8)。
表8
实施例9
配方9:软胶囊由含天然虾青素的雨生红球藻提取物(含有20%虾青素)制备(表9)。
表9
实施例10
配方10:软胶囊由含天然虾青素的雨生红球藻提取物(含有5%虾青素)制备(表10)。
表10
实施例11
配方11:软胶囊由含天然虾青素的雨生红球藻提取物(含有10%虾青素)制备(表11)。
表11
实施例12
配方12:软胶囊由含天然虾青素的雨生红球藻提取物(含有5%虾青素)制备(表12)。
表12
实施例13
配方13:软胶囊由含天然虾青素的雨生红球藻提取物(含有10%虾青素)制备(表13)。
表13
实施例14
配方14:软胶囊由含天然虾青素的雨生红球藻提取物(含有5%虾青素)制备(表14)。
表14
实施例15
配方15:软胶囊由含天然虾青素的雨生红球藻提取物(含有20%虾青素)制备(表15)。
表15:
安排48名健康受试者(男性=24,女性=24,平均年龄=42)服用配方8至15的软胶囊(含有雨生红球藻提取物)补充8周,每组6名健康受试者。在补充期之前和之后,受试者进行最大跑步测试(测在跑步机上的VO2max值)和最大自行车测试(测在自行车测力计上的瓦特值)。
结果显示,当给予所有健康受试者营养补充剂时,8种配方的营养补充剂对于需氧阈值(AeT)和厌氧阈值(AT)收缩时降低心率是有效的。配方11组比其他组更有效。与安慰剂组相比,配方11组(AX、D-α-生育酚、姜黄素/姜黄和矢车菊素-3-葡萄糖苷)中的受试者显示在次最大跑步强度下(在需氧阈值AeT和厌氧阈值AT两者下)显著降低约10%的平均心率,营养补充剂在健康成人中可以降低约18次搏动/分钟(bpm)和/或15次搏动/分钟(bpm)的平均心率。
本申请不应被解释为反映任何权利要求需要比该权利要求中明确记载的特征更多的特征的意图。相反,正如以下权利要求所反映的,创造性方面在于少于任何单个前述公开的实施例的所有特征的组合。因此,在此具体实施方式之后的权利要求书特此明确地并入本具体实施方式中,其中每个权利要求独立地作为单独的实施例。本申请包括独立权利要求及其从属权利要求的所有排列。
对于本领域技术人员显而易见的是,在不背离本申请的基本原理的情况下,可以对上述实施方式的细节做出改变。
Claims (22)
1.一种营养补充剂,其特征在于,包括:
雨生红球藻提取物(50%),以及
可食用载体油(例如中链甘油三酯或类似的食用油)(48%)和
天然抗氧化剂(例如D-α-生育酚或其他天然抗氧化剂)(2%)。
2.根据权利要求1所述的营养补充剂,其特征在于,所述营养补充剂包括1mg~100mg的来源于雨生红球藻提取物的虾青素。
3.根据权利要求1-2中任一项所述的营养补充剂,其特征在于,所述营养补充剂被配制为软凝胶胶囊。
4.根据权利要求1-3中任一项所述的营养补充剂,其特征在于,进一步包括以下各项中的一种或多种:
绿茶;
绿茶提取物;
槲皮素;
矢车菊素-3-葡萄糖苷(C3G);
姜黄素/姜黄;
乳香(boswellia);
透明质酸。
5.根据权利要求1-4中任一项所述的营养补充剂,其特征在于,当给予健康成人时,所述营养补充剂对于促进心张力效应是有效的。
6.根据权利要求1-4中任一项所述的营养补充剂,其特征在于,当给予健康成人时,所述营养补充剂对于促进心血管效率的改善是有效的。
7.一种改善受试者心张力效应的方法,其特征在于,所述方法包括:
获得如权利要求1-6中任一项所述的营养补充剂;以及
摄取所述营养补充剂。
8.一种改善受试者心血管效率的方法,其特征在于,所述方法包括:
获得如权利要求1-6中任一项所述的营养补充剂;以及
摄取所述营养补充剂。
9.一种营养补充剂,其特征在于,包含:
雨生红球藻提取物,
可食用载体油,以及
天然抗氧化剂。
10.根据权利要求9所述的营养补充剂,其特征在于,所述可食用载体油是中链甘油三酯。
11.根据权利要求9所述的营养补充剂,其特征在于,所述天然抗氧化剂是D-α-生育酚。
12.根据权利要求9至11中任一项所述的营养补充剂,其特征在于,所述营养补充剂包括:
50%的雨生红球藻提取物,以及
48%的可食用载体油,以及
2%的天然抗氧化剂。
13.根据权利要求9至12中任一项所述的营养补充剂,其特征在于,所述营养补充剂包括1mg~100mg的来源于雨生红球藻提取物的虾青素。
14.根据权利要求9至13中任一项所述的营养补充剂,其特征在于,所述营养补充剂被配制为软凝胶胶囊或液体胶囊。
15.根据权利要求9至14中任一项所述的营养补充剂,其特征在于,进一步包括以下各项中的一种或多种:
绿茶;
绿茶提取物;
槲皮素;
矢车菊素-3-葡萄糖苷(C3G);
姜黄素/姜黄;
乳香(boswellia);
透明质酸。
16.根据权利要求15所述的营养补充剂,其特征在于,所述营养补充剂包括5mg~150mg的绿茶提取物。
17.根据权利要求15所述的营养补充剂,其特征在于,所述营养补充剂包括1mg~200mg的槲皮素。
18.根据权利要求15所述的营养补充剂,其特征在于,所述营养补充剂包括5mg~400mg的C3G。
19.根据权利要求15所述的营养补充剂,其特征在于,所述营养补充剂包括15mg~250mg的姜黄素/姜黄。
20.根据权利要求15所述的营养补充剂,其特征在于,所述营养补充剂包括1mg~100mg的乳香。
21.根据权利要求15所述的营养补充剂,其特征在于,所述营养补充剂包括5mg~150mg的透明质酸。
22.权利要求9-21中任一项所述的营养补充剂在制备促进强心效应或改善心血管效率的药物中的用途。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662404853P | 2016-10-06 | 2016-10-06 | |
US62/404,853 | 2016-10-06 | ||
PCT/CN2017/104837 WO2018064966A1 (en) | 2016-10-06 | 2017-09-30 | Nutritional supplements affecting cardiovascular efficiency |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109789178A true CN109789178A (zh) | 2019-05-21 |
CN109789178B CN109789178B (zh) | 2022-12-16 |
Family
ID=61830781
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201780059452.9A Active CN109789178B (zh) | 2016-10-06 | 2017-09-30 | 影响心血管效率的营养补充剂 |
Country Status (6)
Country | Link |
---|---|
US (1) | US10827775B2 (zh) |
EP (1) | EP3522903B1 (zh) |
JP (1) | JP7329245B2 (zh) |
CN (1) | CN109789178B (zh) |
PL (1) | PL3522903T3 (zh) |
WO (1) | WO2018064966A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT17695U1 (de) * | 2021-12-20 | 2022-11-15 | Bdi Holding Gmbh | Astaxanthin-haltige paste, deren herstellung und verwendungen |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101053409A (zh) * | 2007-05-11 | 2007-10-17 | 汪昔奇 | 含有天然虾青素的保健食品 |
CN104643100A (zh) * | 2015-02-11 | 2015-05-27 | 浙江康恩贝集团医疗保健品有限公司 | 一种具有抗氧化功能的保健食品 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030008048A1 (en) | 2001-06-08 | 2003-01-09 | David Winston | Methods and compositions for helping the body resist the effects of the aging process |
JP2007238441A (ja) | 2004-12-03 | 2007-09-20 | Fuji Chem Ind Co Ltd | アスタキサンチンを有効成分とする体脂肪減少用組成物 |
JP2006347927A (ja) * | 2005-06-14 | 2006-12-28 | Fuji Chem Ind Co Ltd | 疲労改善剤 |
JP2008179632A (ja) * | 2006-12-29 | 2008-08-07 | Fuji Chem Ind Co Ltd | 抗酸化剤 |
CN100542545C (zh) | 2007-03-28 | 2009-09-23 | 汪昔奇 | 一种天然虾青素-鱼肝油胶囊的制备方法 |
JP5334492B2 (ja) * | 2008-08-13 | 2013-11-06 | 富士化学工業株式会社 | 高濃度アスタキサンチン抽出物 |
JP2011063547A (ja) * | 2009-09-17 | 2011-03-31 | Fuji Chem Ind Co Ltd | 無酸素性運動向上剤及び無酸素性運動向上用の食品 |
US20110117207A1 (en) * | 2009-11-17 | 2011-05-19 | U.S. Nutraceuticals, LLC d/b/a Valensa International State of Incorporation: | Use of eggshell membrane formulations to alleviate joint pain |
KR101332064B1 (ko) | 2011-06-28 | 2013-11-22 | 한국콜마주식회사 | 나노에멀젼 조성물 및 그 제조방법 |
JP2015110526A (ja) * | 2013-08-09 | 2015-06-18 | 富士化学工業株式会社 | 歯肉保護剤 |
JP6428107B2 (ja) | 2014-09-29 | 2018-11-28 | 株式会社村田製作所 | 蓄電装置、電子機器、電動車両および電力システム |
CN104351807A (zh) | 2014-10-15 | 2015-02-18 | 苏州唐基生物科技有限公司 | 一种具有抗氧化功能的植物源组合物 |
CN105394749B (zh) * | 2015-10-23 | 2018-03-20 | 武汉龙族药号生物医药科技有限公司 | 一种含有虾青素的保健食品配方及制备方法和应用 |
CN105582001A (zh) | 2015-12-25 | 2016-05-18 | 南京泛成生物化工有限公司 | 一种虾青素组合物、制剂及其制备方法 |
JP6734101B2 (ja) * | 2016-03-31 | 2020-08-05 | 富士化学工業株式会社 | 心拍数回復促進組成物 |
-
2017
- 2017-09-30 WO PCT/CN2017/104837 patent/WO2018064966A1/en unknown
- 2017-09-30 JP JP2019540483A patent/JP7329245B2/ja active Active
- 2017-09-30 CN CN201780059452.9A patent/CN109789178B/zh active Active
- 2017-09-30 PL PL17857847T patent/PL3522903T3/pl unknown
- 2017-09-30 EP EP17857847.2A patent/EP3522903B1/en active Active
- 2017-09-30 US US16/337,223 patent/US10827775B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101053409A (zh) * | 2007-05-11 | 2007-10-17 | 汪昔奇 | 含有天然虾青素的保健食品 |
CN104643100A (zh) * | 2015-02-11 | 2015-05-27 | 浙江康恩贝集团医疗保健品有限公司 | 一种具有抗氧化功能的保健食品 |
Non-Patent Citations (3)
Title |
---|
ROBERT G等: "Astaxanthin in cardiovascular health and disease", 《MOLECULES》 * |
常芸: "运动性心律失常研究现状与展望", 《中国运动医学杂志》 * |
郑建仙: "《功能性食品》", 30 September 1999, 中国轻工业出版社 * |
Also Published As
Publication number | Publication date |
---|---|
PL3522903T3 (pl) | 2022-01-31 |
JP7329245B2 (ja) | 2023-08-18 |
US10827775B2 (en) | 2020-11-10 |
US20190289892A1 (en) | 2019-09-26 |
EP3522903B1 (en) | 2021-11-03 |
EP3522903A4 (en) | 2020-04-01 |
CN109789178B (zh) | 2022-12-16 |
WO2018064966A1 (en) | 2018-04-12 |
JP2020503061A (ja) | 2020-01-30 |
EP3522903A1 (en) | 2019-08-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2019200802B2 (en) | Synergistic dietary supplement compositions for enhancing physical performance | |
CN103750143B (zh) | 耐缺氧型抗疲劳能量组合物及其应用 | |
CN103766736B (zh) | 抗疲劳能量组合物及其应用 | |
US11122829B2 (en) | Dietary supplements and compositions for enhancing physical performance and energy levels | |
Zafeiridis | The effects of dietary nitrate (beetroot juice) supplementation on exercise performance: A review | |
CN106937709A (zh) | 一种护肤亮毛的天然犬粮组合物及其制备方法 | |
D’Angelo et al. | The impact of supplementation with Pomegranate fruit (Punica Granatum L.) on sport performance | |
CN103919052A (zh) | 用于体能恢复的组合物及其应用 | |
Capelli et al. | Role of astaxanthin in sports nutrition | |
US6159476A (en) | Herbal supplement for increased muscle strength and endurance for athletes | |
RU2468609C1 (ru) | Продукт белково-витаминный для питания спортсменов | |
CN109789178A (zh) | 影响心血管效率的营养补充剂 | |
Hornsby | The effects of carbohydrate-electrolyte sports drinks on performance and physiological function during an 8km cycle time trial | |
Talbott et al. | Effect of astaxanthin supplementation on cardiorespiratory function in runners | |
Hecht et al. | Astaxanthin for improved muscle function and enhanced physical performance | |
US8603546B2 (en) | Herbal supplement for increased muscle strength and endurance for athletes | |
Ammatul et al. | Development of protein rich products using spirulina | |
KR20170014237A (ko) | 발효 흑마늘 및 흑양파가 포함된 젤리스틱 및 이의 제조방법 | |
TW201300102A (zh) | 使用茉莉酸改善骨骼肌功能 | |
Cook et al. | Metabolic and Physiological Responses by New Zealand Blackcurrant during Cycling: A Dose-Response Study | |
CA3221915A1 (en) | Compositions comprising curcuminoids for use in the treatment of muscle soreness | |
JP2024015087A (ja) | 経口組成物 | |
CN103535574B (zh) | 一种蜂王浆组合物及其制备方法 | |
Boynton et al. | Beet Shot Supplements to Improve Endurance Performance in Cyclists and Runners: 552 May 28, 2: 45 PM-3: 00 PM | |
Cunniffe et al. | The Acute Effects of Citrulline-Malate Supplementation on High Intensity Cycling Performance and Muscle Oxygenation: 551 May 28, 2: 30 PM-2: 45 PM |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230418 Address after: 652200 core area of Shilin eco industrial concentration area, Lufu sub district office, Shilin Yi Autonomous County, Kunming City, Yunnan Province Patentee after: Yunnan Yuncai Jinke astaxanthin Biotechnology Co.,Ltd. Address before: Room 1706, block a, building 1, Tianzuo International Center, No. 12, Zhongguancun South Street, Haidian District, Beijing 100081 Patentee before: BEIJING GINGKO GROUP BIOLOGICAL TECHNOLOGY Co.,Ltd. |